Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Alnylam Pharmaceuticals reported a significant decline in revenue for Q3 2024, with total revenue of $500.92 million, down 33.3% year-over-year, and an EPS of -$0.50 compared to $1.15 a year ago [1] - The reported revenue fell short of the Zacks Consensus Estimate of $529.34 million, resulting in a surprise of -5.37% [1] Revenue Performance - Net Product Revenue for Oxlumo in the U.S. was $14.93 million, slightly below the average estimate of $15.73 million, but showed a year-over-year increase of 53.7% [3] - Net Product Revenue for Amvuttra in the U.S. reached $168.66 million, exceeding the average estimate of $153.83 million, with a year-over-year growth of 48.6% [3] - Net Product Revenue for Givlaari in the U.S. was $40.37 million, below the average estimate of $42.96 million, but still represented a 9.1% increase year-over-year [3] - Net Product Revenue for Onpattro in the U.S. was $16.21 million, below the average estimate of $18.23 million, reflecting a year-over-year decline of 25.9% [3] - Total net product revenues amounted to $420.15 million, surpassing the 10-analyst average estimate of $414.11 million, with a year-over-year increase of 34.2% [3] - Royalty revenue was reported at $23.39 million, exceeding the average estimate of $22.32 million, marking a significant year-over-year increase of 136.1% [3] - Net revenues from research collaborators were $57.39 million, falling short of the average estimate of $96.03 million [3] Stock Performance - Alnylam's shares have returned +3.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a +1% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]